How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

- Tiong, Ing Soo, Wall, Meaghan, Marlton, Paula, Johnston, Amanda, Enjeti, Anoop, Fong, Chun Yew, Cull, Gavin, Larsen, Stephen, Kennedy, Glen, Schwarer, Anthony, Kipp, David, Ramanathan, Sundra, Bajel, Ashish, Verner, Emma, Tiley, Campbell, Morris, E, Hahn, U, Moore, J, Taper, J, Purtill, D, Warburton, P, Stevenson, W, Murphy, N, Kalro, Akash, Tan, P, Beligaswatte, A, Mutsando, H, Hertzberg, M, Shortt, J, Szabo, F, Dunne, K, Wei, AH, Australasian Leukaemia and Lymphoma Group (ALLG),, Fleming, Shaun, Roberts, Andrew W., Thiagarajah, Nisha, Chua, Chong Chyn, Latimer, Maya, Yeung, David

Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies

- Germon, Zacary P., Sillar, Jonathan R., McLachlan, Tabitha, Schjenken, John E., Skerrett-Byrne, David A., Huang, Honggang, Melo-Braga, Marcella N., Plank, Maximillan W., Alvaro, Frank, Chamberlain, Janis, De Iuliis, Geoff, Aitken, R. John, Mannan, Abdul, Nixon, Brett, Wei, AH, Enjeti, Anoop K., Huang, Y, Lock, RB, Larsen, MR, Lee, Heather, Vaghjiani, V, Cain, JE, de Bock, CE, Duchatel, Ryan J., Verrills, Nicole M., Dun, Matthew D., Staudt, Dilana, Murray, Heather C., Findlay, Izac J., Jackson, Evangeline R., McEwen, Holly P., Douglas, Alicia M.

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

- Loo, Sun, Roberts, Andrew W., Taper, John, Cull, Gavin, Tiley, Campbell, Verner, Emma, Hahn, Uwe, Hiwase, Devendra K., Iland, Harry J., Murphy, Nick, Ramanathan, Sundra, Reynolds, John, Anstee, Natasha S., Ong, DM, Tiong, IS, Wall, M, Murray, M, Rawling, T, Leadbetter, J, Rowley, L, Latimer, M, Yuen, SLS, Ting, SB, Kennedy, Glen A., Fong, CY, Morris, KL, Bajel, A, Seymour, JF, Levis, MJ, Wei, AH, He, Simon, Schwarer, Anthony P., Enjeti, Anoop K., D'Rozario, James, Marlton, Paula, Bilmon, Ian A.